Crescent Biopharma, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • CBIO (NCM)

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

617-430-5595 300 Fifth Avenue, Waltham, MA 02451, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →

Q2 2025 Neutral

Jun 18, 2025

CRESCENT BIOPHARMA, INC. (CBIO) Q2 2025 earnings call transcript directs stakeholders to Exhibits 99.2, 99.3, and 99.4 for unaudited financial statements, management's discussion, and pro forma combined financial information. No specific financial results, guidance, or operational highlights were detailed within the provided text, requiring a review of the full filings for comprehensive insights into the quarter's performance.

Recent News

Two experimental cancer drugs cleared to begin human trials in U.S., China - Stock Titan

Stock Titan • Jan 5

The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Stocktwits

Stocktwits • Dec 4

With 36% stake, Crescent Biopharma, Inc. (NASDAQ:CBIO) seems to have captured institutional investors' interest - Yahoo Finance

Yahoo Finance • Sep 17

Crescent Biopharma announces regulatory clearance of IND applications - TipRanks

TipRanks • Jan 5

Crescent Biopharma stock soars after Kelun-Biotech partnership - Investing.com

Investing.com • Dec 4

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has CRESCENT BIOPHARMA, INC. had layoffs?

No layoff events have been recorded for CRESCENT BIOPHARMA, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does CRESCENT BIOPHARMA, INC. have?

CRESCENT BIOPHARMA, INC. has approximately 41 employees.

What industry is CRESCENT BIOPHARMA, INC. in?

CRESCENT BIOPHARMA, INC. operates in the Biotechnology industry, within the Healthcare sector.

Is CRESCENT BIOPHARMA, INC. a publicly traded company?

Yes, CRESCENT BIOPHARMA, INC. is publicly traded under the ticker symbol CBIO on the NCM. The company has a market capitalization of approximately $0.21 billion.

Where is CRESCENT BIOPHARMA, INC. headquartered?

CRESCENT BIOPHARMA, INC. is headquartered in Waltham, MA, United States at 300 Fifth Avenue, Waltham, MA 02451, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.